Generic semaglutide is approved in Canada. Access must come next.
Dr. Sanjeev Sockalingam explains what generic semaglutide approval means for obesity care, access, and coverage for Canadians.
obesitycanada.caHere’s the latest on generic semaglutide in Canada.
-
Health Canada has approved the first generic semaglutide injection in Canada, making Canada the first G7 country to authorize a generic version of the Ozempic/Wegovy active ingredient. The approval applies to a generic semaglutide product manufactured by Dr. Reddy’s Laboratories and is intended for once-weekly treatment of adults with type 2 diabetes to help manage blood sugar. Health Canada indicated that additional generic submissions were under review, with more decisions expected in the coming weeks and months.[1][3][4]
-
A second generic semaglutide injection, manufactured by Apotex (Canadian-based), was also approved, further expanding access and potential price competition in Canada. Health Canada stated it is reviewing multiple other submissions for generic semaglutide and will continue monitoring safety and effectiveness across all authorized products.[2][3]
-
Canada’s 2026 approvals position Health Canada as the first government in the G7 to authorize generic semaglutide, with ongoing reviews of additional submissions and anticipated market entries in the near term. Early reports and industry analysis suggested that generic entry could reduce list prices and increase patient access, though exact price reductions depend on the number of competing generics and provincial reimbursement policies.[3][4][1]
-
Canadian health system coverage and patient access will depend on provincial formularies and private plans, as well as post-market safety monitoring by Health Canada. Health Canada’s statements emphasize safety, efficacy, and quality as the basis for the generic approvals and ongoing pharmacovigilance.[4][3]
Key takeaways
- Canada is the first G7 country to approve generic semaglutide, with at least two generics now authorized (Dr. Reddy’s and Apotex) and more submissions under review. The landscape is still developing, with price and access outcomes contingent on market competition and payer decisions. Health Canada is actively monitoring safety across all approved generics.[1][2][3][4]
If you’d like, I can pull brief summaries of each approved product’s labeling, approved indications, and typical price expectations from Canadian sources, and format them in a comparison table. I can also set up a watch list to alert you to further Health Canada updates as they’re posted.